PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma.

PGP9.5/UCHL1 is a member of the carboxyl-terminal ubiquitin hydrolase family with a potential role in carcinogenesis. We previously identified PGP9.5 as a putative tumor-suppressor gene and methylation of the promoter as a cancer-specific event in primary cancer tissues. In this current study, we analyzed PGP9.5 methylation in 50 esophageal squamous cell carcinoma (ESCC) primary tumors with well characterized clinicopathologic variables including patient outcome. Two independent modalities for methylation analysis (TaqMan methylation-specific PCR and combined bisulfite restriction analysis) were used to analyze these samples. The two data sets were consistent with each other, as the 21 patients (42%) with highest methylation levels by TaqMan analysis all showed visible combined bisulfite restriction analysis bands on acrylamide gels. Using an optimized cutoff value by TaqMan quantitation, we found that patients with higher PGP9.5 methylation ratios in the primary tumor showed poorer 5-year survival rates than those without PGP9.5 methylation (P = 0.01). A significant correlation was also seen between PGP9.5 promoter methylation and the presence of regional lymph node metastases (P = 0.03). Multivariate analysis subsequently revealed that PGP9.5 methylation was an independent prognostic factor for ESCC survival (P = 0.03). These results suggest that PGP9.5 promoter methylation could be a clinically applicable marker for ESCC progression.

[1]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[2]  Tsung-Teh Wu,et al.  Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  M. Urashima,et al.  Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer. , 2004, Cancer letters.

[4]  K. Joh,et al.  Ubiquitin immunoreactivity in human malignant tumours. , 1991, British Journal of Cancer.

[5]  S. Nomoto,et al.  Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing , 2004, Cancer Research.

[6]  J. Ferlay,et al.  Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.

[7]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[8]  K D Wilkinson,et al.  The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. , 1989, Science.

[9]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[10]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[11]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[12]  Hiroshi Nakayama,et al.  PGP9.5 overexpression in esophageal squamous cell carcinoma. , 2003, Hepato-gastroenterology.

[13]  A. Nakao,et al.  PGP9.5 as a prognostic factor in pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  S. Hirohashi,et al.  Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver. , 1997, Journal of hepatology.

[15]  F. Sato,et al.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. , 2002, Cancer cell.

[16]  J. Cameron,et al.  Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. , 2003, Cancer research.

[17]  K. Sugimachi,et al.  Simple Staging Criteria for Esophageal Carcinoma: Classification With a Strict Prognostic Stratification , 2003, American journal of clinical oncology.

[18]  Peter A. Jones.  DNA methylation and cancer , 2002, Oncogene.

[19]  M. Koike,et al.  Histopathologic characteristics of early stage esophageal carcinoma: A comparative study with gastric carcinoma , 2010, Cancer.

[20]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[21]  K. Wada,et al.  Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. , 2004, The American journal of pathology.

[22]  K. Sugimachi,et al.  Prognostic factors of esophageal carcinoma: Univariate and multivariate analyses , 1986, Journal of surgical oncology.

[23]  S. Groshen,et al.  Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.